切換：
- 簡略
- 詳細(MARC)
- ISBD
-
ADVANCES IN CLINICAL CHEMISTRY DUP_3
紀錄類型 ： 書目-語言資料,印刷品: 單行本
出版者 ： [S.l.] :ELSEVIER ACADEMIC PRESS,2022.
面頁冊數 ： 1 online resource
內容註 ： Intro -- Advances in Clinical Chemistry -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Advances in quantum dots as diagnostic tools -- 1. Introduction -- 2. Quantum dots: Synthesis, functionalization and characterization -- 2.1. Synthetic procedures -- 2.1.1. Top-down processing methods -- 2.1.2. Bottom-up processing methods -- 2.2. Solubilization and functionalization -- 2.2.1. Aqueous stabilization of QDs -- 2.2.2. Bioconjugation of QDs -- 2.3. Analytical tools for QD characterization -- 2.3.1. Morphological information -- 2.3.2. Crystallographic information -- 2.3.3. Chemical composition -- 2.3.4. Surface characterization -- 2.3.5. Bioconjugation efficiency -- 3. Quantum dots for point-of-care (POC) diagnosis -- 3.1. POC devices: Role of QDs -- 3.2. Optical and electrochemical methods for QD biosensing tag detection -- 3.3. POC systems based on QD barcode technology -- 3.4. Paper-based POC diagnostic devices using QDs -- 3.4.1. Lateral-flow principles: Optical detection -- 3.4.2. Smartphone integration -- 3.4.3. Paper-based devices with electrochemical detection -- 3.4.4. Emerging nanopaper platforms -- 4. Ultrasensitive biomarker detection based on quantum dots -- 5. Bioconjugated quantum dots for molecular imaging -- 5.1. Bioconjugated QDs for fluorescence molecular imaging -- 5.2. Near-infrared optical imaging -- 5.3. Multimodal imaging -- 6. Summary and future perspectives -- Acknowledgments -- References -- Chapter Two: Host polymorphisms and COVID-19 infection -- 1. Introduction -- 2. Genetic polymorphisms affecting the angiotensin-converting enzyme 2 expression (Table 1) -- 2.1. Angiotensin-converting enzyme 2 -- 2.2. Transmembrane serine protease 2 -- 2.3. Androgen receptor -- 2.4. A disintegrin and metalloproteinase 17 -- 2.5. Angiotensin-converting enzyme 1.
內容註 ： 3. Genetic polymorphisms affecting the immune response against COVID-19 (Table 2) -- C-C chemokine receptor 5 -- 3.2. Complement C3 -- 3.3. Interferon-induced transmembrane protein 3 -- 3.4. Tumor necrosis factor-alpha -- 3.5. Toll-like receptor 7 -- 3.6. Apolipoprotein E -- 3.7. Vitamin D binding protein -- 3.8. Dipeptidyl peptidase -- 3.9. Glutathione S-transferase theta 1 -- 4. Associated genetic polymorphisms (Table 3) -- 4.1. ABO blood group -- 4.2. Human leukocyte antigen system -- 4.3. Haplogroup R -- 4.4. Neanderthal DNA -- 5. Conclusion -- References -- Chapter Three: Clinical metabolomics for inborn errors of metabolism -- 1. Introduction -- 2. Overview of metabolomics -- 3. Overview of inborn error of metabolism laboratory diagnosis -- 4. Analytical methodology -- 4.1. Sample extraction -- 4.2. Analytical instrumentation and methods -- 4.3. The importance of library-based bioinformatics methodology -- 4.4. Authentic standard library -- 4.5. Quality control and data alignment -- 4.6. Data curation -- 5. Computations for reference population comparisons -- 6. Bridging to reference populations and other analytical considerations -- 6.1. Bridging to the reference population -- 6.2. Process quality control -- 6.3. Compound performance criteria -- 6.3.1. Analytical performance -- 6.3.1.1. Precision studies -- 6.3.1.2. Platform correlation studies -- 6.3.1.3. Median ratio studies -- 6.3.1.4. Compound stability studies -- 6.3.2. Biological relevance -- 6.4. Preanalytical sample quality assessment -- 6.5. Reporting and limitations -- 7. Clinical utility of metabolomics for the identification of IEMs -- 7.1. Application in rare disease profiling -- 7.2. Rare disease characterization and therapeutic monitoring -- 7.3. Adjunct to exome sequencing -- 8. Future applications and challenges -- 9. Conclusions -- References.
內容註 ： Chapter Four: Amino acids in inflammatory bowel diseases: Modern diagnostic tools and methodologies -- 1. Introduction -- 2. Inflammatory bowel diseases -- 2.1. Risk factors of IBD -- 2.2. Therapy of inflammatory bowel disease -- 3. Biomarkers of inflammatory bowel disease -- 4. Amino acids as biomarkers and their role in inflammatory bowel disease -- 5. Analytical strategies for analysis of amino acids in biological samples -- 5.1. Sample preparation -- 5.1.1. Solid-phase extraction and solid-phase microextraction -- 5.1.2. Liquid-liquid extraction -- 5.1.3. Protein precipitation -- 5.1.4. Electrophoretic preconcentration -- 5.1.5. Derivatization -- 5.2. Chromatographic techniques -- 5.2.1. Detection in liquid chromatography -- 5.2.2. Practical applications of chromatographic methods in bioanalysis of amino acids -- 5.3. Capillary electrophoresis -- 5.3.1. Detection in capillary electrophoresis -- 5.3.2. Practical applications of electromigration methods in bioanalysis of amino acids -- 6. Current studies of amino acids in IBD -- 7. Conclusion -- Acknowledgments -- Conflict of interest -- References -- Chapter Five: Advances in sports genomics -- 1. Introduction -- 2. Genome-wide association (GWAS) and whole genome sequencing (WGS) studies in sport -- 2.1. Genome-wide association studies -- 2.2. Whole genome sequencing study -- 3. Gene variants for endurance athlete status -- 4. Gene variants for power athlete status -- 5. Gene variants for strength athlete status -- 6. Gene variants for soft tissue injuries -- 7. Conclusion -- References -- Chapter Six: Biomarkers in muscle invasive bladder cancer -- 1. Introduction -- 2. Current treatment of MIBC -- 2.1. Cystectomy versus radiotherapy -- 2.2. Radiosensitizing agents -- 2.3. Neoadjuvant and adjuvant therapy -- 3. The unmet need for robust biomarkers in MIBC -- 4. Urinary biomarkers.
內容註 ： 5. Gene expression signatures predicting lymph node metastasis -- 6. Biomarkers of anti-tumor immunity -- 6.1. PD-1/PD-L1 -- 6.2. Lymphocytopenia -- 7. Hypoxia biomarkers -- 8. Biomarkers of DNA damage repair -- 8.1. MRE11 -- 8.2. ERCC1 and XRCC1 -- 8.3. ATM/RB1/FANCC -- 8.4. AIMP3 -- 9. Clinical trials of poly ADP ribose polymerase (PARP) inhibitors -- 10. Other molecular biomarkers -- 10.1. p53 -- 10.2. EGFR family -- 11. Molecular taxonomy -- 12. The fibroblast growth factor receptor (FGFR) pathway -- 13. Liquid biopsy -- 14. Micro-RNA -- 15. Conclusion -- Funding -- Acknowledgments -- References -- Index.
標題 ： Biochemistry. -
標題 ： Clinical medicine. -
標題 ： Biochemistry -
標題 ： Clinical Medicine -
ISBN ： 9780323988483
ISBN ： 0323988482
LEADER 07156nam 2200325M 4500
001 52491
003 NhCcYBP
005 20230927145034.4
006 m o d
007 cr |n|||||||||
008 220326s2022 xx o 0|| 0 eng d
020 $a9780323988483$q(electronic bk.)
020 $a0323988482$q(electronic bk.)
020 $z0323988377
020 $z9780323988377
020 $z9780323988476$q(e-book)
035 $aebs3227846
040 $aNhCcYBP$cNhCcYBP
041 $aeng
050 4$aRB40$b.A383 2022
082 04$a616.0756
245 00$aADVANCES IN CLINICAL CHEMISTRY DUP_3$h[electronic resource].
260 $a[S.l.] :$bELSEVIER ACADEMIC PRESS,$c2022.
300 $a1 online resource
505 0 $aIntro -- Advances in Clinical Chemistry -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Advances in quantum dots as diagnostic tools -- 1. Introduction -- 2. Quantum dots: Synthesis, functionalization and characterization -- 2.1. Synthetic procedures -- 2.1.1. Top-down processing methods -- 2.1.2. Bottom-up processing methods -- 2.2. Solubilization and functionalization -- 2.2.1. Aqueous stabilization of QDs -- 2.2.2. Bioconjugation of QDs -- 2.3. Analytical tools for QD characterization -- 2.3.1. Morphological information -- 2.3.2. Crystallographic information -- 2.3.3. Chemical composition -- 2.3.4. Surface characterization -- 2.3.5. Bioconjugation efficiency -- 3. Quantum dots for point-of-care (POC) diagnosis -- 3.1. POC devices: Role of QDs -- 3.2. Optical and electrochemical methods for QD biosensing tag detection -- 3.3. POC systems based on QD barcode technology -- 3.4. Paper-based POC diagnostic devices using QDs -- 3.4.1. Lateral-flow principles: Optical detection -- 3.4.2. Smartphone integration -- 3.4.3. Paper-based devices with electrochemical detection -- 3.4.4. Emerging nanopaper platforms -- 4. Ultrasensitive biomarker detection based on quantum dots -- 5. Bioconjugated quantum dots for molecular imaging -- 5.1. Bioconjugated QDs for fluorescence molecular imaging -- 5.2. Near-infrared optical imaging -- 5.3. Multimodal imaging -- 6. Summary and future perspectives -- Acknowledgments -- References -- Chapter Two: Host polymorphisms and COVID-19 infection -- 1. Introduction -- 2. Genetic polymorphisms affecting the angiotensin-converting enzyme 2 expression (Table 1) -- 2.1. Angiotensin-converting enzyme 2 -- 2.2. Transmembrane serine protease 2 -- 2.3. Androgen receptor -- 2.4. A disintegrin and metalloproteinase 17 -- 2.5. Angiotensin-converting enzyme 1.
505 8 $a3. Genetic polymorphisms affecting the immune response against COVID-19 (Table 2) -- C-C chemokine receptor 5 -- 3.2. Complement C3 -- 3.3. Interferon-induced transmembrane protein 3 -- 3.4. Tumor necrosis factor-alpha -- 3.5. Toll-like receptor 7 -- 3.6. Apolipoprotein E -- 3.7. Vitamin D binding protein -- 3.8. Dipeptidyl peptidase -- 3.9. Glutathione S-transferase theta 1 -- 4. Associated genetic polymorphisms (Table 3) -- 4.1. ABO blood group -- 4.2. Human leukocyte antigen system -- 4.3. Haplogroup R -- 4.4. Neanderthal DNA -- 5. Conclusion -- References -- Chapter Three: Clinical metabolomics for inborn errors of metabolism -- 1. Introduction -- 2. Overview of metabolomics -- 3. Overview of inborn error of metabolism laboratory diagnosis -- 4. Analytical methodology -- 4.1. Sample extraction -- 4.2. Analytical instrumentation and methods -- 4.3. The importance of library-based bioinformatics methodology -- 4.4. Authentic standard library -- 4.5. Quality control and data alignment -- 4.6. Data curation -- 5. Computations for reference population comparisons -- 6. Bridging to reference populations and other analytical considerations -- 6.1. Bridging to the reference population -- 6.2. Process quality control -- 6.3. Compound performance criteria -- 6.3.1. Analytical performance -- 6.3.1.1. Precision studies -- 6.3.1.2. Platform correlation studies -- 6.3.1.3. Median ratio studies -- 6.3.1.4. Compound stability studies -- 6.3.2. Biological relevance -- 6.4. Preanalytical sample quality assessment -- 6.5. Reporting and limitations -- 7. Clinical utility of metabolomics for the identification of IEMs -- 7.1. Application in rare disease profiling -- 7.2. Rare disease characterization and therapeutic monitoring -- 7.3. Adjunct to exome sequencing -- 8. Future applications and challenges -- 9. Conclusions -- References.
505 8 $aChapter Four: Amino acids in inflammatory bowel diseases: Modern diagnostic tools and methodologies -- 1. Introduction -- 2. Inflammatory bowel diseases -- 2.1. Risk factors of IBD -- 2.2. Therapy of inflammatory bowel disease -- 3. Biomarkers of inflammatory bowel disease -- 4. Amino acids as biomarkers and their role in inflammatory bowel disease -- 5. Analytical strategies for analysis of amino acids in biological samples -- 5.1. Sample preparation -- 5.1.1. Solid-phase extraction and solid-phase microextraction -- 5.1.2. Liquid-liquid extraction -- 5.1.3. Protein precipitation -- 5.1.4. Electrophoretic preconcentration -- 5.1.5. Derivatization -- 5.2. Chromatographic techniques -- 5.2.1. Detection in liquid chromatography -- 5.2.2. Practical applications of chromatographic methods in bioanalysis of amino acids -- 5.3. Capillary electrophoresis -- 5.3.1. Detection in capillary electrophoresis -- 5.3.2. Practical applications of electromigration methods in bioanalysis of amino acids -- 6. Current studies of amino acids in IBD -- 7. Conclusion -- Acknowledgments -- Conflict of interest -- References -- Chapter Five: Advances in sports genomics -- 1. Introduction -- 2. Genome-wide association (GWAS) and whole genome sequencing (WGS) studies in sport -- 2.1. Genome-wide association studies -- 2.2. Whole genome sequencing study -- 3. Gene variants for endurance athlete status -- 4. Gene variants for power athlete status -- 5. Gene variants for strength athlete status -- 6. Gene variants for soft tissue injuries -- 7. Conclusion -- References -- Chapter Six: Biomarkers in muscle invasive bladder cancer -- 1. Introduction -- 2. Current treatment of MIBC -- 2.1. Cystectomy versus radiotherapy -- 2.2. Radiosensitizing agents -- 2.3. Neoadjuvant and adjuvant therapy -- 3. The unmet need for robust biomarkers in MIBC -- 4. Urinary biomarkers.
505 8 $a5. Gene expression signatures predicting lymph node metastasis -- 6. Biomarkers of anti-tumor immunity -- 6.1. PD-1/PD-L1 -- 6.2. Lymphocytopenia -- 7. Hypoxia biomarkers -- 8. Biomarkers of DNA damage repair -- 8.1. MRE11 -- 8.2. ERCC1 and XRCC1 -- 8.3. ATM/RB1/FANCC -- 8.4. AIMP3 -- 9. Clinical trials of poly ADP ribose polymerase (PARP) inhibitors -- 10. Other molecular biomarkers -- 10.1. p53 -- 10.2. EGFR family -- 11. Molecular taxonomy -- 12. The fibroblast growth factor receptor (FGFR) pathway -- 13. Liquid biopsy -- 14. Micro-RNA -- 15. Conclusion -- Funding -- Acknowledgments -- References -- Index.
533 $aElectronic reproduction.$bIpswich, MA$nAvailable via World Wide Web.
650 0$aClinical chemistry.$328447
650 0$aBiochemistry.$328740
650 0$aClinical medicine.$314526
650 2$aChemistry, Clinical$312784
650 2$aBiochemistry$312492
650 2$aClinical Medicine$312169
710 2 $aEBSCOhost$387894
776 08$cOriginal$z0323988377$z9780323988377
856 40$uhttps://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3029005$zClick to View (限總院院內)
ADVANCES IN CLINICAL CHEMISTRY DUP_3[electronic resource]. - [S.l.] :ELSEVIER ACADEMIC PRESS,2022. - 1 online resource
Intro -- Advances in Clinical Chemistry -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Advances in quantum dots as diagnostic tools -- 1. Introduction -- 2. Quantum dots: Synthesis, functionalization and characterization -- 2.1. Synthetic procedures -- 2.1.1. Top-down processing methods -- 2.1.2. Bottom-up processing methods -- 2.2. Solubilization and functionalization -- 2.2.1. Aqueous stabilization of QDs -- 2.2.2. Bioconjugation of QDs -- 2.3. Analytical tools for QD characterization -- 2.3.1. Morphological information -- 2.3.2. Crystallographic information -- 2.3.3. Chemical composition -- 2.3.4. Surface characterization -- 2.3.5. Bioconjugation efficiency -- 3. Quantum dots for point-of-care (POC) diagnosis -- 3.1. POC devices: Role of QDs -- 3.2. Optical and electrochemical methods for QD biosensing tag detection -- 3.3. POC systems based on QD barcode technology -- 3.4. Paper-based POC diagnostic devices using QDs -- 3.4.1. Lateral-flow principles: Optical detection -- 3.4.2. Smartphone integration -- 3.4.3. Paper-based devices with electrochemical detection -- 3.4.4. Emerging nanopaper platforms -- 4. Ultrasensitive biomarker detection based on quantum dots -- 5. Bioconjugated quantum dots for molecular imaging -- 5.1. Bioconjugated QDs for fluorescence molecular imaging -- 5.2. Near-infrared optical imaging -- 5.3. Multimodal imaging -- 6. Summary and future perspectives -- Acknowledgments -- References -- Chapter Two: Host polymorphisms and COVID-19 infection -- 1. Introduction -- 2. Genetic polymorphisms affecting the angiotensin-converting enzyme 2 expression (Table 1) -- 2.1. Angiotensin-converting enzyme 2 -- 2.2. Transmembrane serine protease 2 -- 2.3. Androgen receptor -- 2.4. A disintegrin and metalloproteinase 17 -- 2.5. Angiotensin-converting enzyme 1.
Electronic reproduction.
Ipswich, MA
Available via World Wide Web.
ISBN: 9780323988483Subjects--Topical Terms:
28447
Clinical chemistry.
LC Class. No.: RB40 / .A383 2022
Dewey Class. No.: 616.0756
Intro -- Advances in Clinical Chemistry -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Advances in quantum dots as diagnostic tools -- 1. Introduction -- 2. Quantum dots: Synthesis, functionalization and characterization -- 2.1. Synthetic procedures -- 2.1.1. Top-down processing methods -- 2.1.2. Bottom-up processing methods -- 2.2. Solubilization and functionalization -- 2.2.1. Aqueous stabilization of QDs -- 2.2.2. Bioconjugation of QDs -- 2.3. Analytical tools for QD characterization -- 2.3.1. Morphological information -- 2.3.2. Crystallographic information -- 2.3.3. Chemical composition -- 2.3.4. Surface characterization -- 2.3.5. Bioconjugation efficiency -- 3. Quantum dots for point-of-care (POC) diagnosis -- 3.1. POC devices: Role of QDs -- 3.2. Optical and electrochemical methods for QD biosensing tag detection -- 3.3. POC systems based on QD barcode technology -- 3.4. Paper-based POC diagnostic devices using QDs -- 3.4.1. Lateral-flow principles: Optical detection -- 3.4.2. Smartphone integration -- 3.4.3. Paper-based devices with electrochemical detection -- 3.4.4. Emerging nanopaper platforms -- 4. Ultrasensitive biomarker detection based on quantum dots -- 5. Bioconjugated quantum dots for molecular imaging -- 5.1. Bioconjugated QDs for fluorescence molecular imaging -- 5.2. Near-infrared optical imaging -- 5.3. Multimodal imaging -- 6. Summary and future perspectives -- Acknowledgments -- References -- Chapter Two: Host polymorphisms and COVID-19 infection -- 1. Introduction -- 2. Genetic polymorphisms affecting the angiotensin-converting enzyme 2 expression (Table 1) -- 2.1. Angiotensin-converting enzyme 2 -- 2.2. Transmembrane serine protease 2 -- 2.3. Androgen receptor -- 2.4. A disintegrin and metalloproteinase 17 -- 2.5. Angiotensin-converting enzyme 1.
Electronic reproduction.
Ipswich, MA
Available via World Wide Web.
ISBN: 9780323988483Subjects--Topical Terms:
28447
Clinical chemistry.
LC Class. No.: RB40 / .A383 2022
Dewey Class. No.: 616.0756
- 館藏(0)
- 心得(0)
- 標籤
- 相同喜好的讀者(0)
- 相關資料(0)
發表心得